Skip to main content

Drug Interaction Report

1 potential interaction and/or warning found for the following 2 drugs:

Filter by interaction and/or warning

Interactions between your drugs

Moderate

fluconazole rifabutin

Applies to: Diflucan (fluconazole), rifabutin

GENERALLY AVOID: Concomitant administration of fluconazole has been shown to increase the maximum serum concentration of rifabutin and to decrease rifabutin clearance. The mechanism is inhibition of CYP450 3A4 hepatic microsomal enzymes. Additionally, rifabutin may increase the metabolism of fluconazole due to induction of CYP450 metabolism. Subtherapeutic levels of the azole may result.

MANAGEMENT: Concomitant use of fluconazole and rifabutin should generally be avoided, if concomitant use is necessary, patients should be monitored for rifabutin toxicity (e.g., neutropenia, uveitis). Antimicrobial activity should be monitored, and dosages should be adjusted as needed.

References (3)
  1. Trapnell CB, Narang PK, Li R, Lavelle JP (1996) "Increased plasma rifabutin levels with concomitant fluconazole therapy in HIV-infected patients." Ann Intern Med, 124, p. 573-6
  2. Jordan MK, Polis MA, Kelly G, Narang PK, Masur H, Piscitelli SC (2000) "Effects of fluconazole and clarithromycin on rifabutin and 25-O-desacetylrifabutin pharmacokinetics." Antimicrob Agents Chemother, 44, p. 2170-72
  3. (2020) "Product Information. Talicia (amoxicillin/omeprazole/rifabutin)." RedHill Biopharma Inc.

Drug and food interactions

No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No duplication warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

See also:

Learn more

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.